Menu
← Oncology Approval Tracker
FDA DECISION ·
Ayvakit
avapritinib · Blueprint Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with indolent systemic mastocytosis.
LAMPGEN ANALYSIS
Why it matters
The expansion added a targeted treatment for an indolent mast cell neoplasm, distinct from the prior advanced-disease use.
What research teams should watch
Record the mastocytosis subtype and use indication-specific dosing and platelet monitoring.
PRIMARY RECORDS